



## Clinical trial results:

### A Phase 2b, 12-Week, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Multicenter Study of the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor

#### Summary

EudraCT number	2020-002463-61
Trial protocol	DE ES PL
Global end of trial date	30 May 2024

#### Results information

Result version number	v1 (current)
This version publication date	15 June 2025
First version publication date	15 June 2025

#### Trial information

##### Trial identification

Sponsor protocol code	JZP385-201
-----------------------	------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT05122650
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Jazz Pharmaceuticals, Inc.
Sponsor organisation address	3170 Porter Drive, Palo Alto, United States, 94304
Public contact	Director Clinical Trial Disclosure & Transparency, Jazz Pharmaceuticals, Inc., +1 215-832-3750, ClinicalTrialDisclosure@JazzPharma.com
Scientific contact	Director Clinical Trial Disclosure & Transparency, Jazz Pharmaceuticals, Inc., +1 215-832-3750, ClinicalTrialDisclosure@JazzPharma.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	07 June 2024
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	30 May 2024
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The primary objective of the trial was to evaluate the efficacy of JZP385 to improve functional and performance-based impairment due to tremor when administered QD for up to 12 weeks at fixed doses of 10, 20, and 30 mg/day.

Protection of trial subjects:

The protocol, protocol amendments, ICF, investigator brochure, and other relevant documents (eg, advertisements) were submitted to an IRB/IEC by the investigator and reviewed and approved by the IRB/IEC before the study was initiated.

This study was conducted in accordance with the protocol and consensus ethical principles derived from international guidelines including the Declaration of Helsinki, Council for International Organizations of Medical Sciences International Ethical Guidelines, applicable ICH GCP Guidelines, and other applicable laws and regulations.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	06 December 2021
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	United States: 205
Country: Number of subjects enrolled	Germany: 28
Country: Number of subjects enrolled	Poland: 151
Country: Number of subjects enrolled	Spain: 36
Worldwide total number of subjects	420
EEA total number of subjects	215

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23	0

months)	
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	187
From 65 to 84 years	233
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

A total of 420 participants were randomized to treatment. These 420 participants are included in the Intent to Treat Analysis set (ITT). Of those 420 participants, only 416 received at least 1 dose of study intervention. Four participants did not receive any treatment. These 416 participants are included in the Safety Analysis Set.

### Pre-assignment

Screening details:

The screening Period lasted up to 35 days, with an additional 28 days were permitted for participants who required washout of restricted medications.

### Period 1

Period 1 title	Overall Period (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Placebo

Arm description:

Participants will receive placebo from Day 1.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Patients were instructed to take this intervention in the morning QD on an empty stomach.

<b>Arm title</b>	10 milligram (mg) JZP385
------------------	--------------------------

Arm description:

Participants will initially receive 5 mg/day from Day 1 through Day 7, and 10 mg/day starting on Day 8.

Arm type	Experimental
Investigational medicinal product name	JZP385
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Patients were instructed to take this intervention in the morning QD on an empty stomach.

<b>Arm title</b>	20 mg JZP385
------------------	--------------

Arm description:

Participants will initially receive 5 mg/day from Day 1 through Day 7, 10 mg/day from Day 8 through Day 14, and 20 mg/day starting on Day 15.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	JZP385
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Patients were instructed to take this intervention in the morning QD on an empty stomach.

<b>Arm title</b>	30 mg JZP385
------------------	--------------

Arm description:

Participants will initially receive 5 mg/day from Day 1 through Day 7, 10 mg/day from Day 8 through Day 14, 20 mg/day from Day 15 through Day 21, and 30 mg/day starting on Day 22.

Arm type	Experimental
Investigational medicinal product name	JZP385
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Patients were instructed to take this intervention in the morning QD on an empty stomach.

<b>Number of subjects in period 1</b>	Placebo	10 milligram (mg) JZP385	20 mg JZP385
Started	104	105	104
Completed	91	78	81
Not completed	13	27	23
Consent withdrawn by subject	3	7	4
Adverse event, non-fatal	4	16	11
Not specified	5	-	-
Sponsor request	-	1	1
Randomized by mistake	-	-	3
Non-compliance with study intervention	-	-	-
Lost to follow-up	1	1	3
Lack of efficacy	-	1	1
Protocol deviation	-	1	-

<b>Number of subjects in period 1</b>	30 mg JZP385
Started	107
Completed	78
Not completed	29
Consent withdrawn by subject	8
Adverse event, non-fatal	12
Not specified	-
Sponsor request	2

Randomized by mistake	2
Non-compliance with study intervention	2
Lost to follow-up	-
Lack of efficacy	2
Protocol deviation	1

## Baseline characteristics

### Reporting groups

Reporting group title	Placebo
Reporting group description: Participants will receive placebo from Day 1.	
Reporting group title	10 milligram (mg) JZP385
Reporting group description: Participants will initially receive 5 mg/day from Day 1 through Day 7, and 10 mg/day starting on Day 8.	
Reporting group title	20 mg JZP385
Reporting group description: Participants will initially receive 5 mg/day from Day 1 through Day 7, 10 mg/day from Day 8 through Day 14, and 20 mg/day starting on Day 15.	
Reporting group title	30 mg JZP385
Reporting group description: Participants will initially receive 5 mg/day from Day 1 through Day 7, 10 mg/day from Day 8 through Day 14, 20 mg/day from Day 15 through Day 21, and 30 mg/day starting on Day 22.	

Reporting group values	Placebo	10 milligram (mg) JZP385	20 mg JZP385
Number of subjects	104	105	104
Age Categorical Units: Subjects			

Gender categorical Units: Subjects			
Female	41	37	33
Male	63	68	71
Age categorical Units: Subjects			
<= 18 years	0	0	0
Between 18 and 65	43	51	45
>= 65 years	61	54	59
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	1	0	0
Asian	0	1	0
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	0	4
White	98	96	93
More than one race	0	1	1
Unknown or Not Reported	5	7	6
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	11	10	9
Not Hispanic or Latino	93	95	95
Unknown or Not Reported	0	0	0

Reporting group values	30 mg JZP385	Total	
------------------------	--------------	-------	--

Number of subjects	107	420	
Age Categorical Units: Subjects			
Gender categorical Units: Subjects			
Female	49	160	
Male	58	260	
Age categorical Units: Subjects			
<= 18 years	0	0	
Between 18 and 65	48	187	
>= 65 years	59	233	
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	0	1	
Asian	0	1	
Native Hawaiian or Other Pacific Islander	0	0	
Black or African American	4	8	
White	92	379	
More than one race	2	4	
Unknown or Not Reported	9	27	
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	11	41	
Not Hispanic or Latino	96	379	
Unknown or Not Reported	0	0	



## End points

### End points reporting groups

Reporting group title	Placebo
Reporting group description: Participants will receive placebo from Day 1.	
Reporting group title	10 milligram (mg) JZP385
Reporting group description: Participants will initially receive 5 mg/day from Day 1 through Day 7, and 10 mg/day starting on Day 8.	
Reporting group title	20 mg JZP385
Reporting group description: Participants will initially receive 5 mg/day from Day 1 through Day 7, 10 mg/day from Day 8 through Day 14, and 20 mg/day starting on Day 15.	
Reporting group title	30 mg JZP385
Reporting group description: Participants will initially receive 5 mg/day from Day 1 through Day 7, 10 mg/day from Day 8 through Day 14, 20 mg/day from Day 15 through Day 21, and 30 mg/day starting on Day 22.	
Subject analysis set title	Placebo
Subject analysis set type	Intention-to-treat
Subject analysis set description: Participants will receive placebo from Day 1.	
Subject analysis set title	10 milligram (mg) JZP385
Subject analysis set type	Intention-to-treat
Subject analysis set description: Participants will initially receive 5 mg/day from Day 1 through Day 7, and 10 mg/day starting on Day 8.	
Subject analysis set title	20 mg JZP385
Subject analysis set type	Intention-to-treat
Subject analysis set description: Participants will initially receive 5 mg/day from Day 1 through Day 7, 10 mg/day from Day 8 through Day 14, and 20 mg/day starting on Day 15.	
Subject analysis set title	30 mg JZP385
Subject analysis set type	Intention-to-treat
Subject analysis set description: Participants will initially receive 5 mg/day from Day 1 through Day 7, 10 mg/day from Day 8 through Day 14, 20 mg/day from Day 15 through Day 21, and 30 mg/day starting on Day 22.	

### Primary: Change from Baseline to Week 12 on the TETRAS composite outcome score as summarized by each dose of JZP385 and placebo

End point title	Change from Baseline to Week 12 on the TETRAS composite outcome score as summarized by each dose of JZP385 and placebo <sup>[1]</sup>
End point description: The TETRAS composite outcome score is the sum of modified items 1 - 11 of the TETRAS-ADL subscale and modified items 6 - 7 of the TETRAS-PS. The TETRAS-ADL subscale is a patient-rated scale administered by a trained interviewer that assesses the impact of tremor on day-to-day functioning, such as eating, drinking, dressing, and other fine motor skills. The TETRAS-PS is a clinical rating scale that quantifies tremor in the head, face voice, limbs and trunk. Items 6 (drawing an Archimedes spiral using left and right hands) and 7 (handwriting) of the TETRAS-PS evaluate the impact of upper limb tremor on performance. Each item from the modified subscales ranges from 0 - 3, with 0 representing normal or slightly abnormal and 3 representing severely abnormal. The sum of the 14 items provides the TETRAS composite outcome score, which ranges from 0 - 42, with higher scores representing more severe ET.	
End point type	Primary
End point timeframe: Change from baseline to week 12	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive analyses were used to assess this outcome measure.

End point values	Placebo	10 milligram (mg) JZP385	20 mg JZP385	30 mg JZP385
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	94	79	82	78
Units: score on a scale				
arithmetic mean (standard deviation)	-6.3 (± 6.22)	-5.8 (± 6.85)	-6.7 (± 6.88)	-7.5 (± 7.31)

## Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Participants who Improved (≥ 1-Point Improvement) from Baseline to Week 12 on the Clinical Global Impression- Severity scale (CGI-S)

End point title	Percentage of Participants who Improved (≥ 1-Point Improvement) from Baseline to Week 12 on the Clinical Global Impression- Severity scale (CGI-S)
-----------------	--

End point description:

The CGI-S is a 5-point Likert-type rating scale that a qualified medical personnel (ie, a clinician) will use to rate the severity of the participants' ability to function due to their ET. The responses to this scale range from 1 (no limitations) to 5 (severe).

End point type	Secondary
----------------	-----------

End point timeframe:

Change from baseline to week 12

End point values	Placebo	10 milligram (mg) JZP385	20 mg JZP385	30 mg JZP385
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	104	105	104	107
Units: Percentage of participants				
number (not applicable)	50.0	49.8	55.7	62.8

## Statistical analyses

No statistical analyses for this end point

### Secondary: Proportion of Participants Reported as Much Improved on the Patient Global Impression of Change (PGI-C) at Week 12

End point title	Proportion of Participants Reported as Much Improved on the Patient Global Impression of Change (PGI-C) at Week 12
-----------------	--

End point description:

The PGI-C is a 5-point Likert-type rating scale that participants use to rate the change in severity of their ability to function due to ET since baseline. The responses to this scale range from 1 (Much

improved) to 5 (Much worse).

End point type	Secondary
End point timeframe:	
Change from baseline to week 12	

End point values	Placebo	10 milligram (mg) JZP385	20 mg JZP385	30 mg JZP385
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	94	79	82	79
Units: participants				
number (not applicable)	16	11	20	32

### Statistical analyses

No statistical analyses for this end point

#### Secondary: Proportion of Participants Reported as Much Improved on the Clinical Global Impression of Change (CGI-C) at Week 12

End point title	Proportion of Participants Reported as Much Improved on the Clinical Global Impression of Change (CGI-C) at Week 12
-----------------	---

End point description:

The CGI-C is a 5-point Likert-type rating scale that a qualified medical personnel (ie, a clinician) will use to rate the change in severity of the participants' ability to function due to their ET since baseline. The responses to this scale range from 1 (Much improved) to 5 (Much worse).

End point type	Secondary
End point timeframe:	
Week 12	

End point values	Placebo	10 milligram (mg) JZP385	20 mg JZP385	30 mg JZP385
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	94	79	82	79
Units: participants	22	18	19	30

### Statistical analyses

No statistical analyses for this end point

#### Secondary: Change from Baseline to Week 12 on the TETRAS-ADL subscale as Summarized by Each Dose of JZP385 and Placebo

End point title	Change from Baseline to Week 12 on the TETRAS-ADL subscale as Summarized by Each Dose of JZP385 and Placebo
-----------------	---

End point description:

The TETRAS-ADL subscale is a patient-rated scale of the impact of tremor on day-to-day functioning administered by a trained interviewer. The TETRAS-ADL subscale directly measures how a patient functions by assessing activities impacted by tremor, such as eating and drinking, dressing and personal hygiene, carrying items, and fine motor skills. The TETRAS-ADL has 12 items and each item is rated on a 0 (normal) to 4 (severe) scale, with higher scores representing more severe ET.

End point type	Secondary
----------------	-----------

End point timeframe:

Change from baseline to week 12

End point values	Placebo	10 milligram (mg) JZP385	20 mg JZP385	30 mg JZP385
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	94	79	82	79
Units: score on a scale				
arithmetic mean (standard deviation)	-6.4 (± 6.40)	-6.3 (± 7.55)	-7.1 (± 7.88)	-8.7 (± 8.49)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline to Week 12 on the TETRAS-PS Subscale as Summarized by Each Dose of JZP385 and Placebo

End point title	Change from Baseline to Week 12 on the TETRAS-PS Subscale as Summarized by Each Dose of JZP385 and Placebo
-----------------	--

End point description:

The TETRAS-PS is a clinical rating scale performed by a blinded rater that quantifies tremor in the head, face, voice, limbs, and trunk. Each item will be rated on a scale of 0 (normal) to 4 (severe). The sum of the individual scores provides the overall score, ranging from 0 to 64, with higher scores representing more severe ET.

End point type	Secondary
----------------	-----------

End point timeframe:

Change from baseline to week 12

End point values	Placebo	10 milligram (mg) JZP385	20 mg JZP385	30 mg JZP385
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	94	79	82	78
Units: score on a scale				
arithmetic mean (standard deviation)	-5.4 (± 5.73)	-5.3 (± 6.57)	-5.1 (± 6.15)	-5.5 (± 6.27)

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline to Week 12 on the Upper Limb Score (item 4) of the TETRAS-PS as Summarized by Each Dose of JZP385 and Placebo

End point title	Change from Baseline to Week 12 on the Upper Limb Score (item 4) of the TETRAS-PS as Summarized by Each Dose of JZP385 and Placebo
End point description: Item 4 of the TETRAS-PS measures upper limb tremor, and includes 3 maneuvers for each arm that assess postural and kinetic tremor. Each item is rated on a scale of 0 (normal) to 4 (severe) in 0.5-point increments. The total score is the sum of each of the 6 items and ranges from 0 to 24, with higher scores representing more severe ET. The TETRAS-PS is performed by a blinded rater.	
End point type	Secondary
End point timeframe: Change from baseline to week 12	

End point values	Placebo	10 milligram (mg) JZP385	20 mg JZP385	30 mg JZP385
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	94	79	82	78
Units: score on a scale				
arithmetic mean (standard deviation)	-2.3 (± 2.68)	-2.4 (± 2.78)	-2.0 (± 2.61)	-2.4 (± 2.81)

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline to Week 12 on the TETRAS Total Score, as Summarized by Each Dose of JZP385 and Placebo.

End point title	Change from Baseline to Week 12 on the TETRAS Total Score, as Summarized by Each Dose of JZP385 and Placebo.
End point description: The TETRAS total score is the sum of the scores of the full TETRAS-ADL and TETRAS-PS subscales. Each item is rated on a 0 (normal) to 4 (severe) scale, and total scores range from 0 to 112, with higher scores representing more severe ET. The TETRAS-PS is performed by a blinded rater.	
End point type	Secondary
End point timeframe: Change from baseline to week 12	

End point values	Placebo	10 milligram (mg) JZP385	20 mg JZP385	30 mg JZP385
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	94	79	82	78
Units: score on a scale				
arithmetic mean (standard deviation)	-11.8 (± 10.18)	-11.6 (± 11.54)	-12.3 (± 11.95)	-14.4 (± 12.20)

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline to Week 12 on the Quality of Life in Essential Tremor Questionnaire (QUEST) as Summarized by Each Dose of JZP385 and Placebo

End point title	Change from Baseline to Week 12 on the Quality of Life in Essential Tremor Questionnaire (QUEST) as Summarized by Each Dose of JZP385 and Placebo
-----------------	---

End point description:

The Quality of Life in Essential Tremor Questionnaire (QUEST) was developed to specifically assess the impact of ET on health-related quality of life. The QUEST is a 30-item questionnaire comprising 5 subscales (physical, psychosocial, communication, hobbies/leisure, and work/finance). Each item is rated by frequency on a scale from 0 (never) to 4 (always), with higher scores indicating greater dissatisfaction or disability due to ET.

End point type	Secondary
----------------	-----------

End point timeframe:

Change from baseline to week 12

End point values	Placebo	10 milligram (mg) JZP385	20 mg JZP385	30 mg JZP385
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	99	100	95	98
Units: score on a scale				
arithmetic mean (standard deviation)				
Communication Subscale Total Score	-5.5 (± 15.35)	-3.3 (± 15.62)	-3.5 (± 14.67)	-7.8 (± 16.18)
Work and Finance Subscale Total Score	-5.8 (± 16.44)	1.0 (± 17.26)	-6.1 (± 15.61)	-6.7 (± 15.11)
Hobbies and Leisure Subscale Total Score	-1.1 (± 29.35)	-8.9 (± 31.66)	-3.5 (± 36.50)	-10.2 (± 33.81)
Physical Subscale Total Score	-11.0 (± 17.65)	-5.1 (± 17.60)	-10.1 (± 16.85)	-13.4 (± 20.24)
Psychosocial Subscale Total Score	-6.8 (± 14.93)	-2.9 (± 16.57)	-6.1 (± 15.79)	-6.2 (± 15.40)

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline to Week 12 on the Essential Tremor Embarrassment Assessment (ETEA) Score A as Summarized by Each Dose of JZP385 and Placebo

End point title	Change from Baseline to Week 12 on the Essential Tremor Embarrassment Assessment (ETEA) Score A as Summarized by Each Dose of JZP385 and Placebo
-----------------	--

End point description:

The Essential Tremor Embarrassment Assessment (ETEA) is a participant-rated questionnaire administered by a health care provider or researcher that contains 14-items assessing embarrassment related to tremor. For Score A, participants provide a simple response (disagree or agree) to each of the 14-items, the sum of which yields an initial score range = 0 to 14. Higher scores indicate greater embarrassment.

End point type	Secondary
----------------	-----------

End point timeframe:

Change from baseline to week 12

End point values	Placebo	10 milligram (mg) JZP385	20 mg JZP385	30 mg JZP385
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	98	99	95	97
Units: score on a scale				
arithmetic mean (standard deviation)	-0.6 (± 2.84)	-0.5 (± 3.06)	-0.6 (± 3.60)	-1.2 (± 3.51)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline to Week 12 on the Essential Tremor Embarrassment Assessment (ETEA) Score B as Summarized by Each Dose of JZP385 and Placebo

End point title	Change From Baseline to Week 12 on the Essential Tremor Embarrassment Assessment (ETEA) Score B as Summarized by Each Dose of JZP385 and Placebo
-----------------	--

End point description:

The Essential Tremor Embarrassment Assessment (ETEA) is a participant-rated questionnaire administered by a health care provider or researcher that contains 14-items assessing embarrassment related to tremor. For Score B, participants provide a more nuanced response to each question on a 0 to 5 point Likert scale ranging from disagree (0) to agree strongly (5). The sum of the nuanced responses yields a second score (range = 0 to 70). Higher scores indicate greater embarrassment.

End point type	Secondary
----------------	-----------

End point timeframe:

Change from baseline to week 12

End point values	Placebo	10 milligram (mg) JZP385	20 mg JZP385	30 mg JZP385
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	98	99	95	97
Units: score on a scale				
arithmetic mean (standard deviation)	-4.2 (± 12.87)	-3.5 (± 14.15)	-4.6 (± 14.42)	-5.6 (± 14.28)

## Statistical analyses

---

No statistical analyses for this end point



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Adverse events were collected from baseline up to 14 weeks.

Adverse event reporting additional description:

AEs were only collected in the 416 participants who received at least 1 dose of study treatment.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	27
--------------------	----

### Reporting groups

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Participants will receive placebo from Day 1.

Reporting group title	20 mg JZP385
-----------------------	--------------

Reporting group description:

Participants will initially receive 5 mg/day from Day 1 through Day 7, 10 mg/day from Day 8 through Day 14, and 20 mg/day starting on Day 15.

Reporting group title	30 mg JZP385
-----------------------	--------------

Reporting group description:

Participants will initially receive 5 mg/day from Day 1 through Day 7, 10 mg/day from Day 8 through Day 14, 20 mg/day from Day 15 through Day 21, and 30 mg/day starting on Day 22.

Reporting group title	10 milligram (mg) JZP385
-----------------------	--------------------------

Reporting group description:

Participants will initially receive 5 mg/day from Day 1 through Day 7, and 10 mg/day starting on Day 8.

Serious adverse events	Placebo	20 mg JZP385	30 mg JZP385
Total subjects affected by serious adverse events			
subjects affected / exposed	3 / 104 (2.88%)	4 / 103 (3.88%)	4 / 105 (3.81%)
number of deaths (all causes)	1	0	0
number of deaths resulting from adverse events	1	0	0
Injury, poisoning and procedural complications			
Accidental overdose			
subjects affected / exposed	1 / 104 (0.96%)	0 / 103 (0.00%)	0 / 105 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	0 / 104 (0.00%)	1 / 103 (0.97%)	0 / 105 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foot fracture			

subjects affected / exposed	0 / 104 (0.00%)	1 / 103 (0.97%)	0 / 105 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Limb injury			
subjects affected / exposed	0 / 104 (0.00%)	0 / 103 (0.00%)	1 / 105 (0.95%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 104 (0.00%)	0 / 103 (0.00%)	1 / 105 (0.95%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Coronary artery disease			
subjects affected / exposed	0 / 104 (0.00%)	1 / 103 (0.97%)	0 / 105 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Intercostal neuralgia			
subjects affected / exposed	0 / 104 (0.00%)	0 / 103 (0.00%)	1 / 105 (0.95%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient ischaemic attack			
subjects affected / exposed	0 / 104 (0.00%)	0 / 103 (0.00%)	0 / 105 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	0 / 104 (0.00%)	0 / 103 (0.00%)	0 / 105 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Vertigo positional			

subjects affected / exposed	0 / 104 (0.00%)	0 / 103 (0.00%)	1 / 105 (0.95%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Respiratory, thoracic and mediastinal disorders</b>			
Dyspnoea			
subjects affected / exposed	0 / 104 (0.00%)	0 / 103 (0.00%)	0 / 105 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 104 (0.00%)	0 / 103 (0.00%)	1 / 105 (0.95%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary fibrosis			
subjects affected / exposed	1 / 104 (0.96%)	0 / 103 (0.00%)	0 / 105 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
<b>Infections and infestations</b>			
Abscess limb			
subjects affected / exposed	0 / 104 (0.00%)	1 / 103 (0.97%)	0 / 105 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	1 / 104 (0.96%)	0 / 103 (0.00%)	0 / 105 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 104 (0.00%)	1 / 103 (0.97%)	0 / 105 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Serious adverse events</b>			
	10 milligram (mg) JZP385		
Total subjects affected by serious adverse events			
subjects affected / exposed	3 / 104 (2.88%)		
number of deaths (all causes)	0		

number of deaths resulting from adverse events	0		
Injury, poisoning and procedural complications			
Accidental overdose			
subjects affected / exposed	0 / 104 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Fall			
subjects affected / exposed	0 / 104 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Foot fracture			
subjects affected / exposed	0 / 104 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Limb injury			
subjects affected / exposed	0 / 104 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 104 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Coronary artery disease			
subjects affected / exposed	0 / 104 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Intercostal neuralgia			
subjects affected / exposed	0 / 104 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Transient ischaemic attack			

subjects affected / exposed	1 / 104 (0.96%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	1 / 104 (0.96%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Ear and labyrinth disorders			
Vertigo positional			
subjects affected / exposed	0 / 104 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	1 / 104 (0.96%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pulmonary embolism			
subjects affected / exposed	0 / 104 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulmonary fibrosis			
subjects affected / exposed	0 / 104 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Abscess limb			
subjects affected / exposed	0 / 104 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urinary tract infection			

subjects affected / exposed	0 / 104 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonia			
subjects affected / exposed	0 / 104 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Placebo	20 mg JZP385	30 mg JZP385
Total subjects affected by non-serious adverse events			
subjects affected / exposed	20 / 104 (19.23%)	35 / 103 (33.98%)	46 / 105 (43.81%)
Nervous system disorders			
Disturbance in attention			
subjects affected / exposed	0 / 104 (0.00%)	6 / 103 (5.83%)	4 / 105 (3.81%)
occurrences (all)	0	6	4
Dizziness			
subjects affected / exposed	7 / 104 (6.73%)	11 / 103 (10.68%)	12 / 105 (11.43%)
occurrences (all)	9	14	15
Tremor			
subjects affected / exposed	2 / 104 (1.92%)	3 / 103 (2.91%)	7 / 105 (6.67%)
occurrences (all)	2	3	7
Headache			
subjects affected / exposed	5 / 104 (4.81%)	3 / 103 (2.91%)	5 / 105 (4.76%)
occurrences (all)	5	3	5
Paraesthesia			
subjects affected / exposed	0 / 104 (0.00%)	6 / 103 (5.83%)	9 / 105 (8.57%)
occurrences (all)	0	6	10
Somnolence			
subjects affected / exposed	4 / 104 (3.85%)	5 / 103 (4.85%)	7 / 105 (6.67%)
occurrences (all)	4	6	8
General disorders and administration site conditions			
Fatigue			

subjects affected / exposed occurrences (all)	1 / 104 (0.96%) 1	3 / 103 (2.91%) 3	7 / 105 (6.67%) 7
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	1 / 104 (0.96%)	4 / 103 (3.88%)	5 / 105 (4.76%)
occurrences (all)	1	5	5
Dry mouth			
subjects affected / exposed	1 / 104 (0.96%)	1 / 103 (0.97%)	5 / 105 (4.76%)
occurrences (all)	1	1	5
Nausea			
subjects affected / exposed	1 / 104 (0.96%)	3 / 103 (2.91%)	4 / 105 (3.81%)
occurrences (all)	2	3	4
Psychiatric disorders			
Anxiety			
subjects affected / exposed	0 / 104 (0.00%)	2 / 103 (1.94%)	3 / 105 (2.86%)
occurrences (all)	0	2	3
Insomnia			
subjects affected / exposed	2 / 104 (1.92%)	3 / 103 (2.91%)	7 / 105 (6.67%)
occurrences (all)	2	3	7
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	5 / 104 (4.81%)	0 / 103 (0.00%)	4 / 105 (3.81%)
occurrences (all)	5	0	5

<b>Non-serious adverse events</b>	10 milligram (mg) JZP385		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	35 / 104 (33.65%)		
Nervous system disorders			
Disturbance in attention			
subjects affected / exposed	2 / 104 (1.92%)		
occurrences (all)	2		
Dizziness			
subjects affected / exposed	11 / 104 (10.58%)		
occurrences (all)	12		
Tremor			
subjects affected / exposed	1 / 104 (0.96%)		
occurrences (all)	3		

Headache subjects affected / exposed occurrences (all)	8 / 104 (7.69%) 8		
Paraesthesia subjects affected / exposed occurrences (all)	1 / 104 (0.96%) 1		
Somnolence subjects affected / exposed occurrences (all)	2 / 104 (1.92%) 2		
General disorders and administration site conditions Fatigue subjects affected / exposed occurrences (all)	4 / 104 (3.85%) 4		
Gastrointestinal disorders Diarrhoea subjects affected / exposed occurrences (all)  Dry mouth subjects affected / exposed occurrences (all)  Nausea subjects affected / exposed occurrences (all)	6 / 104 (5.77%) 6  6 / 104 (5.77%) 6  6 / 104 (5.77%) 6		
Psychiatric disorders Anxiety subjects affected / exposed occurrences (all)  Insomnia subjects affected / exposed occurrences (all)	6 / 104 (5.77%) 6  5 / 104 (4.81%) 5		
Infections and infestations Nasopharyngitis subjects affected / exposed occurrences (all)	6 / 104 (5.77%) 6		



## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
19 May 2021	This amendment was implemented to align with feedback received from the United States Food and Drug Administration (FDA) regarding study endpoints, to correct an error in the hepatic and renal values necessary for participant exclusion, and to add general clarifications throughout the protocol.
15 November 2021	This amendment was implemented to revise text regarding participant rollover into a separate long-term study, remove CYP2C9 inducers from the exclusion criteria, and to make other minor edits.
07 October 2022	The overall rationale for this amendment was to broaden the eligibility criteria and reduce study burden.
10 February 2023	The overall rationale for this amendment was to facilitate participant enrollment by allowing participants to enter the study without having to discontinue concomitant anti-tremor medications, unless these medications (eg, primidone) are prohibited in accordance with other exclusion criteria.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported